Do Not Start Aspirin for Rib Fractures with Reactive Thrombocytosis
In a patient with rib fractures and a platelet count rising from 299 to 407 ×10⁹/L, aspirin should NOT be started. This platelet elevation represents reactive thrombocytosis from trauma, not a thrombotic indication, and aspirin would only increase bleeding risk without improving outcomes in this clinical scenario.
Why Aspirin Is Not Indicated Here
Your patient's rising platelet count (299→407 ×10⁹/L) is a normal physiological response to trauma and inflammation, not a pathological thrombotic state requiring antiplatelet therapy. The evidence clearly shows:
No Mortality or Morbidity Benefit in Rib Fracture Patients
Research specifically examining antiplatelet agents in rib fracture patients found no difference in mortality or pulmonary complications between those on anticoagulants/antiplatelets versus those not on these medications 1. In fact, preinjury antiplatelet use only resulted in longer hospital stays without any protective benefit 1.
Aspirin Increases Bleeding Risk Without Benefit
The FDA label explicitly warns that aspirin causes severe stomach bleeding, with increased risk in patients taking blood thinners or with bleeding problems 2. In your trauma patient with rib fractures, aspirin would:
- Increase transfusion requirements (demonstrated in hip fracture surgery patients on antiplatelet therapy) 3
- Cause greater hemoglobin drops 3
- Provide no protection against venous thromboembolism at this platelet level
When Aspirin IS Indicated in Trauma
The only trauma scenario where aspirin has proven benefit is VTE prophylaxis after major orthopedic surgery (hip fracture, hip/knee arthroplasty), where it reduces symptomatic DVT/PE by 36% and fatal PE by 58% 4. The PEP trial used 160 mg daily starting preoperatively for 35 days 4. However, this is not applicable to isolated rib fractures.
The Platelet Count Context
A platelet count of 407 ×10⁹/L is:
- Within normal range (normal: 150-450 ×10⁹/L)
- Expected reactive thrombocytosis from acute trauma/inflammation
- Not an indication for antiplatelet therapy
Aspirin for primary thrombotic prevention is considered in specific cardiovascular conditions (stable CAD, stroke prevention in atrial fibrillation, peripheral arterial disease) 5, none of which apply to your trauma patient.
Common Pitfall to Avoid
Do not confuse reactive thrombocytosis with thrombotic risk. Elevated platelets after trauma reflect acute phase response and increased thrombopoietin production during healing. Starting aspirin based solely on platelet count elevation would expose the patient to bleeding complications without addressing any actual thrombotic pathology.
What You Should Do Instead
- Monitor the platelet count - it will normalize as inflammation resolves
- Ensure appropriate VTE prophylaxis with mechanical measures (sequential compression devices) or pharmacologic anticoagulation (enoxaparin, heparin) per your institution's trauma protocol
- Focus on pain control and pulmonary hygiene to prevent atelectasis and pneumonia
- Only consider aspirin if the patient has separate cardiovascular indications unrelated to the trauma